Therapy is for the treatment of spasticity due to multiple sclerosis
News
WHO calls for greater investment into research for millions living with long COVID
Modelling indicates a 307% increase in cases identified between 2020 and 2021
ONWARD reports positive results from a pivotal spinal cord injury study
Up-LIFT research achieves primary endpoint with improvement in arm and hand function
HeartBeat.bio and Molecular Devices link up to automate cardiac organoids
Collaboration will involve sophisticated screening for cardiac-based drug discovery
Novartis announces tislelizumab efficacy results from phase 3 trial
Tislelizumab shows favourable safety profile compared to sorafenib among liver cancer patients
Stada launches prostate cancer treatment across 21 European countries
Company is introducing abiraterone film-coated tablets for treating metastatic prostate cancer
Positive phase 3 data for Sanofi’s Dupixent
Research showed significant improvements in signs and symptoms of prurigo nodularis
Individuals Marketer of the Year 2022 categories still open!
You can still submit your entry before the imminent 16 September 2022 deadline – but hurry!
Still time to enter the 2022 Sales Awards!
Get started on your entry for these prestigious awards now – the deadline is 16 September 2022
Communication Awards entries still open!
Entering the singles categories is simple, quick and free, but hurry – the deadline is 16 September 2022
Valneva and VBI announce partnership for hepatitis B vaccine
Collaboration involves the marketing and distribution of PreHevbri across Europe
Neuroplast receives medicinal product designation for Neuro-Cells
Designation paves way for wider applications for several neurodegenerative diseases
UCB reveals new Bimzelx ‘complete skin clearance’ data
Positive data represents a boost for patients with moderate to severe plaque psoriasis
Brainomix and Bridge Biotherapeutics enter artificial intelligence partnership
Link up will utilise Brainomix’s AI software for the assessment of idiopathic pulmonary fibrosis
PhoreMost in drug target discovery collaboration with Roche
PhoreMost will use Siteseeker platform to identify novel targets for Roche’s discovery programmes
